Analysis-Hims expansion may not come in time for risky GLP-1 business

By Amina Niasse NEW YORK, March 2 (Reuters) - Telehealth company Hims & Hers Health, known for its weight-loss drug business, is promising it can diversify away from its reliance on compounded GLP-1 sales in the U.S., but that may not happen soon enough for investors who are growing impatient. Hims ‌drew regulatory scrutiny last month with its plan to launch a $49 version of Novo Nordisk's brand-new Wegovy pill. It quickly reversed course after the U.S. ‌Food and Drug Administration referred the company ...